We specialize in treating the following conditions. Learn more about how we can help with:
– Psoriatic Arthritis
– Ankylosing Spondylitis
– Crohn’s Disease
– Ulcerative Colitis
– Rheumatoid Arthritis
– Psoriatic Arthritis
Treatment for a variety of rheumatologic diseases (Rheumatoid Arthritis, SLE, Ankylosing Spondylitis, Psoriatic Arthritis), gastrointestinal disorders (Crohn’s disease, Ulcerative Colitis), skin diseases (Psoriasis), gout, refractory uveitis, chronic idiopathic urticaria and allergic asthma, relapsing multiple sclerosis and thyroid eye disease. Typically drugs may be injected or infused over one-half to 2 hours every 4-8 weeks and in some cases over 4 hours but every six months starting at 8:00 AM.
Drugs offered include: Infliximab (Remicade), Abatacept (Orencia), Tocilizumab (Actemra), Golimumab (Simponi Aria), Vedolizumab (Entyvio), Ustekinumab (Stelara), Pegloticase (Krystexxa), Belimumab (Benlysta), Rituximab (Rituxan), Omalizumab (Xolair), and Teprotumumab (Tepezza).
Certain drugs are mixed and given by injection such as lyophillized Certolizimab (Cimzia) and others injected such as Denosumab (Prolia), Romosozumab (Evenity) and Omalizumab (Xolair).
For patients who are intolerant of oral medication or have contraindications several parenteral options are available:
Boniva (intravenous ibandronate ) is offered as an alternative to oral agents for patients with osteoporosis. Treatments are given every three months and take less than five minutes.
Reclast (zoledronic acid) was the second IV bisphosphonate FDA approved for the treatment of osteoporosis. Treatments are given annually. Treatments are given annually and even every two years when taken for prevention of osteoporosis in high risk individuals.
Prolia (denosumab) is a prescription medicine used to treat osteoporosis in postmenopausal women and men who: with osteoporosis and at high risk for fracture. It is given as an injection twice yearly.
Evenity (romosozumab) Is unique in that it builds new bone and prevents further bone loss. It is given as a subcutaneous injection monthly for one year and then patients start an oral medication.
For patients undergoing invasive dental work involving exposed bone for more information concerning osteonecrosis of the jaw, a rare complication of bisphosphonate treatment and less likely Prolia please go to: http://www.medicalnewstoday.com/articles/40774.php. Patients taking the above agents are also urged to discuss this with their oral surgeons.
For more information concerning a particular drug go to medications.